Background: Anemia frequently occurs in chronic heart failure (CHF) patients and is associated with a poor prognosis. A low hematocrit may result from an increased plasma volume (hemodilution) or from reduced red blood cell volume (true anemia). The prevalence and clinical outcome of CHF patients with hemodilution is unknown.
Methods And Results: The prevalence of anemia and its effect on outcome was examined in 196 patients with CHF. The prevalence of hemodilution was assessed in a subset of 37 ambulatory anemic patients with I131-tagged albumin to measure red blood cell and plasma volume. Clinical outcome was monitored. Sixty-one percent of the CHF patients were anemic. The prevalence of anemia increased from 33% in patients with New York Heart Association class II heart failure to 68% in class IV CHF patients. Survival was reduced in anemic patients compared with patients with a normal hematocrit (P<0.05). In the subset of 37 anemic patients, 17 patients (46%) had hemodilution and 20 patients (54%) had a true anemia. Nine patients with hemodilution died or underwent urgent transplant compared with 4 patients in the true anemia group (P<0.04).
Conclusion: Hemodilution is common in CHF patients. Anemia is associated with a poor prognosis in CHF. Patients with hemodilution tend to do worse than patients with true anemia, which suggests that volume overload may be an important mechanism contributing to the poor outcome in anemic CHF patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1161/01.cir.0000052623.16194.80 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Insights and Opportunities from Multimarker Evaluation of Heart Failure: Lessons from BIOSTAT-HF.
Curr Heart Fail Rep
January 2025
Division of Cardiovascular Medicine, Department of Medicine, University of California, 9394 Medical Center Drive, La Jolla, San Diego, CA, USA.
Purpose Of Review: Heart failure is a complex and heterogenous disease state that affects millions worldwide. Over recent decades, advancements in medical therapy and device implementation have significantly transformed the landscape of heart failure outcomes, while improvements in imaging modalities and greater accessibility to genome sequencing have led to increasing recognition of distinct heart failure endotypes. There is rising evidence to suggest all patients do not benefit equally from intensification of guideline directed medical therapy (GDMT).
View Article and Find Full Text PDFReimbursement policies of Swiss health insurances for the surgical treatment of symptomatic breast hypertrophy: a retrospective cohort study.
Swiss Med Wkly
January 2025
Department of Plastic, Reconstructive and Aesthetic Surgery, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
Background: Patients with symptomatic breast hypertrophy typically suffer from chronic back pain, recurrent skin irritation at the inframammary fold and/or low self-esteem resulting in impaired quality of life. Reduction mammaplasty has been shown to effectively treat symptomatic breast hypertrophy with high patient satisfaction. Despite the obvious benefits, reimbursement requests for reduction mammaplasty are initially often refused by the patient's health insurance company, thereby frequently resulting in additional examinations and eventually extra expenses.
View Article and Find Full Text PDFFactors associated with the presence of Candida spp. in the oral and tracheobronchial secretions of patients admitted to an adult intensive care unit.
Diagn Microbiol Infect Dis
January 2025
Professor at the Department of Physiotherapy, the Postgraduate Program in Health Sciences and the Postgraduate Program in Rehabilitation and Functional Performance Universidade Federal dos Vales do Jequitinhonha e Mucuri, Brazil. Electronic address:
to verify factors associated with the presence of Candida spp. in oral and tracheobronchial secretions of 135 patients admitted to an adult ICU, general of the Santa Casa de Caridade, of Diamantina, Minas Gerais, Brazil. Oral samples showed significant differences between colonized and non-colonized patients in the variables age (p < 0.
View Article and Find Full Text PDFBeating-Heart Coronary Artery Bypass grafting (BH-CABG) in patients with End-Stage Renal Disease (ESRD): comparison of the Society of Thoracic Surgeons (STS) predicted risk with actual outcomes.
J Cardiothorac Surg
January 2025
Department of Surgery, Division of Cardiac Surgery, Jefferson-Einstein Medical Center Philadelphia, Philadelphia, PA, USA.
Background: End-Stage Renal Disease (ESRD) is an independent risk factor in outcomes for traditional coronary artery bypass grafting (TRAD-CAB) utilizing aortic cross-clamping and cardioplegic arrest. In order to determine if Beating-Heart CABG (BH-CABG) techniques offer benefit in patients with ESRD, an analysis of the Society of Thoracic Surgeons (STS) predicted risk versus the actual outcomes was performed.
Methods: Between March 2017 - October 2023, all ESRD patients underwent BH-CABG by a single surgeon at a single institution.
Redo Surgical Aortic Valve Replacement versus Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprosthetic Valves.
Ann Thorac Surg
January 2025
Division of Cardiothoracic Surgery, University of Virginia Health University Hospital, Charlottesville, VA.
Background: Valve-in-valve transcatheter aortic valve replacement (ViV-TAVR) is associated with improved perioperative safety compared to redo surgical aortic valve replacement (redo-SAVR), but long-term outcomes remain uncertain. We therefore compare long-term outcomes of ViV-TAVR and redo-SAVR.
Methods: The study included 1:1 propensity-matched Medicare beneficiaries with degenerated bioprosthetic valves admitted between 09/29/2011 and 12/30/2020 undergoing either redo-SAVR or ViV-TAVR.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!